DDCT antibody
- Known as:
- DDCT (anti-)
- Catalog number:
- orb101707
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- DDCT antibody
Related genes to: DDCT antibody
- Gene:
- DDT NIH gene
- Name:
- D-dopachrome tautomerase
- Previous symbol:
- -
- Synonyms:
- DDCT, MIF2, MIF-2, D-DT
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-06
- Date modifiied:
- 2018-02-16
Related products to: DDCT antibody
Related articles to: DDCT antibody
- Early-life exposure to dichlorodiphenyltrichloroethane (DDT) may increase adult cancer risk, but evidence from Asian populations remains limited. Taiwan's nationwide indoor residual spraying (IRS) program during the 1950s provides a unique setting to examine long-term reproductive cancer risk associated with early-life DDT exposure. We conducted an ecological study using township-level DDT IRS frequency (0-5 times) as the exposure indicator. Individuals born between 1952 and 1958 were followed from 1979 to 2022 for incident reproductive cancers based on data from the Taiwan Cancer Registry. Poisson regression models were applied to estimate relative risks associated with each additional IRS exposure. A total of 109,244 reproductive cancer cases were identified. Each additional DDT spraying round was associated with increased risks of breast, ovarian, corpus uteri, prostate, testicular, and cervical cancers (RRs = 1.01-1.16). Elevated risks were observed for testicular cancer (RR = 1.16, 95% CI: 1.01-1.23) and cervical cancer (RR = 1.01, 95% CI: 1.002-1.02), for which Asian epidemiological evidence remains limited. Higher exposure levels were also associated with differences in stage at diagnosis for breast cancer among women aged ≥55 years and for corpus uteri cancer. Early-life DDT exposure was associated with increased risks of several reproductive cancers. These findings support the Developmental Origins of Health and Disease framework and suggest that environmental exposures during critical developmental windows may influence long-term cancer risk. However, the findings should be interpreted cautiously given the ecological study design and potential residual confounding. - Source: PubMed
Publication date: 2026/06/01
Chang Ya-ChiChang Yu-YinWu Wei-TeChen Pau-Chung - Drug discovery faces escalating costs, extended timelines, and ∼90% failure rates, prompting National Institutes of Health (NIH) and US Food and Drug Adminstration (FDA) guidance to reduce animal testing. As a New Approach Methodology (NAM), zebrafish (Danio rerio) bridges high-throughput in vitro assays and mammalian models. Its genetic tractability, optical transparency, rapid development, high fecundity, and genomic similarity to humans enable cost-effective whole-organism screening across drug development. In this review, we survey zebrafish applications from target identification to regulatory evaluation, and how advances in automation, imaging, artificial intelligence (AI), and genetic engineering are extending its reach. We highlight how zebrafish offer a complementary platform accelerating therapeutic discovery and precision medicine. - Source: PubMed
Publication date: 2026/06/08
Cutinho VeonaWilliams Charles H - Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates significant efficacy in various cancers, predominantly as a subsequent treatment line following multiple prior therapies. When compared to autologous options, allogeneic CAR-T products offer distinct advantages related to cell quality and cost-effectiveness. Because CAR-T cells differ fundamentally from conventional pharmaceuticals, mathematical modeling is essential to elucidate their exposure-response relationships. However, model utility depends on robust parametrization, which requires high-quality data. Although clinical data are expanding rapidly, challenges remain due to their limited availability and fragmentation across different sources. To address this limitation, this work introduces a comprehensive dataset aggregating human clinical trials that utilize allogeneic CAR-T cells for hematological disorders. - Source: PubMed
Publication date: 2026/06/08
Obajtek NataliaLisowski BartekUlaszek SewerynJesionek MonikaPiejko MarcinPolak Sebastian - Traditional risk-adjusted valuation methods in the biotechnology industry exhibit significant limitations when assessing early-stage technologies. These limitations include high failure rates, lengthy development timelines, and substantial research and development (R&D) and commercialization costs, which traditional methods fail to fully incorporate. In this study, we propose a revised valuation methodology, 'modified risk-adjusted NPV' (mrNPV), which addresses R&D costs, probability of success, projected sales, timely risk application, and the cost of failure. The mrNPV method assesses the value of a diabetic drug under development as more than US$3 billion and free cash flow as more than US$300 million compared with the traditional method, demonstrating its applicability in biotechnology valuation and bridging the gap between theoretical frameworks and real-world needs. - Source: PubMed
Publication date: 2026/06/08
Yeon Ju HanKim ChunkyuKang Heung-SikBae Ji-WonKim Jeewon S - Over sixty years ago, Silent Spring, the groundbreaking book by biologist Rachel Carson, raised global awareness of the dangers of uncontrolled pesticide use and contributed to the ban on the use of dichlorodiphenyltrichloroethane (DDT) in the USA. Many years later, it is clear that most of the issues raised in this book remain highly relevant. Today, almost our entire environment is contaminated, sometimes permanently, by pesticides. Yet the chronic toxicity of these substances is still poorly understood. In recent years, a growing body of data seems to link environmental exposure to pesticides with the risk of developing chronic neurological disorders, particularly neurodegenerative diseases. This article will attempt to present a clear and concise review of the literature on the subject, focusing on the most studied conditions, namely Parkinson's disease and Alzheimer's disease. - Source: PubMed
Jedidi ZaydSmeets PaulineLaverdeur JustineJedidi HarounDepierreux Frédérique